Campylobacter pyloridis, gastritis, and peptic ulceration - PubMed (original) (raw)

Review

Campylobacter pyloridis, gastritis, and peptic ulceration

C S Goodwin et al. J Clin Pathol. 1986 Apr.

Abstract

Campylobacter pyloridis is a spiral bacterium which was seen by histopathologists several years before it was cultured in 1982 in Perth, Western Australia. It has unique cellular fatty acids, predominantly tetradecanoic acid and cis-11, 12 methylene octadecanoic acid. It also has a unique ultrastructure which is different from that of other campylobacters. C pyloridis possesses a powerful urease enzyme and produces large amounts of extracellular catalase. Both these features may be important virulence factors, allowing it to occupy a protected niche in the stomach below the mucus layer but above the gastric mucosa. Specific lesions are found in the gastric mucosa, and ultrastructural studies show the presence of adherence pedestals identical with those found with enteropathogenic Escherichia coli of the intestine. Histological examination of gastric biopsy tissue has shown that C pyloridis is strongly associated with active chronic gastritis, when polymorphonuclear leucocytes are present, and is not found on normal mucosa except when a biopsy specimen from elsewhere in the stomach shows active chronic gastritis. When patients with symptoms caused by gastritis are identified dual antibacterial treatment, combining the action of bismuth in the stomach with a systemic antibiotic, can eradicate C pyloridis, with remission of symptoms and restoration of normal epithelial morphology. Most peptic ulcers relapse after modern acid reducing treatment, and antibacterial treatment may be beneficial in preventing relapse.

PubMed Disclaimer

Cited by

Helicobacter pylori related functional dyspepsia in a defined malaysian population.
Nafeeza MI, Isa MR, Kudva MV, Ishak MS, Mazlam MZ, Haron A, Najib R, Shahimi MM. Nafeeza MI, et al. Malays J Med Sci. 2000 Jan;7(1):22-6. Malays J Med Sci. 2000. PMID: 22844211 Free PMC article.
Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori.
Rokkas T, Pursey C, Uzoechina E, Dorrington L, Simmons NA, Filipe MI, Sladen GE. Rokkas T, et al. Gut. 1988 Oct;29(10):1386-91. doi: 10.1136/gut.29.10.1386. Gut. 1988. PMID: 3058555 Free PMC article. Clinical Trial.
The characterization and pathological significance of gastric Campylobacter-like organisms in the ferret: a model for chronic gastritis?
Tompkins DS, Wyatt JI, Rathbone BJ, West AP. Tompkins DS, et al. Epidemiol Infect. 1988 Oct;101(2):269-78. doi: 10.1017/s0950268800054182. Epidemiol Infect. 1988. PMID: 3181311 Free PMC article.
Superior stain for Helicobacter pylori using toluidine O.
Slater B. Slater B. J Clin Pathol. 1990 Nov;43(11):961. doi: 10.1136/jcp.43.11.961-b. J Clin Pathol. 1990. PMID: 1702103 Free PMC article. No abstract available.
Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori.
Glupczynski Y, Labbé M, Hansen W, Crokaert F, Yourassowsky E. Glupczynski Y, et al. J Clin Microbiol. 1991 Sep;29(9):2072-5. doi: 10.1128/jcm.29.9.2072-2075.1991. J Clin Microbiol. 1991. PMID: 1774337 Free PMC article.

References

1. Gut. 1971 Aug;12(8):639-45 - PubMed
1. J Clin Pathol. 1975 Aug;28(8):639-46 - PubMed
1. J Clin Pathol. 1985 Oct;38(10):1127-31 - PubMed
1. Lancet. 1985 May 4;1(8436):1048-9 - PubMed
1. Am J Gastroenterol. 1979 Mar;71(3):269-79 - PubMed

Campylobacter pyloridis, gastritis, and peptic ulceration - PubMed (original) (raw)